Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: Basal Insulin, Bolus Insulin Sep 19 | 2019New MannKind and Dance Inhaled Insulin Data; EASD 2019 Day 4Purchase Blast
$599
Posted in: Basal Insulin Sep 19 | 2019Thoughts on CONCLUDE (H2H Tresiba vs. Toujeo T2DM Basal-only Trial)Purchase Blast
$599
Posted in: SGLT2i Sep 19 | 2019Lexicon +188% Post DAPA-HF and Sanofi Partnership DissolutionPurchase Blast$599
Posted in: Dual/triple agonist, Other Sep 18 | 2019Poxel Ph3 Imeglimin and vTv Ph2 TTP399 CGM Data; EASD 2019 Day 3Purchase Blast$599
Posted in: Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery Sep 17 | 2019New Medtronic Professional CGM; One Drop/Bayer Partnership; EASD 2019 Key Press Releases (Sept 17)Purchase Blast
$599
Posted in: DPP-IVi, GLP-1RA, SGLT2i Sep 16 | 2019REWIND CHMP Opinion This Week?; Dapa/Saxa/Met Opinion Anticipated (CHMP Agenda Sept 16-20)Purchase Blast$599
Posted in: Basal Insulin, Bolus Insulin, Glucose Monitoring, Insulin Delivery, SGLT2i Sep 16 | 2019Farxiga HF Fast Track Designation; New Novo/Medtronic and Sanofi/Abbott PartnershipsPurchase Blast
$599
Posted in: Basal Insulin, GLP-1RA, Glucose Monitoring Sep 13 | 2019Thoughts on Dance/Dario PartnershipPurchase Blast
$599
Posted in: Glucagon Sep 10 | 2019Xeris Glucagon Approved by FDA; Investors Appear UnimpressedPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin Sep 06 | 2019New Novo Insulin Savings ProgramPurchase Blast$599
Posted in: SGLT2i Sep 05 | 2019Lexicon @ Wells Fargo; First Presentation Since DAPA-HF ResultsPurchase Blast
$599
Posted in: Other Sep 05 | 2019New Zafgen Data Suggests Clinical Hold Will Remain; Strategic Options to be ExploredPurchase Blast
$599
Posted in: Basal Insulin Sep 05 | 2019Sanofi Initiates New Toujeo vs. Tresiba T1DM CGM Study (inRange)Purchase Blast
$599
Posted in: Glucose Monitoring Sep 05 | 2019Livongo Stock Plunges After First Post-IPO Earnings Release (Q2 '19)Purchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, GLP-1RA, Other Sep 03 | 2019Biocon/Mylan Glargine CRL; BI/ZEAL Dual Agonist Moves to Ph2; Vertex Acquires SemmaPurchase Blast
Free
Posted in: Other Sep 03 | 2019FENIX to Host EASD Social Event on Monday Sept 16Access Free Blast
$599
Posted in: GLP-1RA, SGLT2i Sep 03 | 2019More Thoughts from DAPA-HF… Could Novo+Lexicon Really Happen?Purchase Blast
$599
Posted in: SGLT2i Sep 01 | 2019DAPA-HF is a Home Run, But Results Remain UnpublishedPurchase BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
